Tom Hughes has more than 30 years of industry experience in the development and commercialization of pharmaceutical products. Tom has served since 2018 as CEO of Navitor Pharmaceuticals, a privately held biopharmaceutical company.
Prior to joining Navitor, Tom served as President and Chief Scientific Officer, and earlier as CEO. During this time, he established Zafgen as a leading biotechnology company working in the area of rare and prevalent metabolic disorders and led the company through its Initial Public Offering in 2014. Prior to Zafgen, Tom held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research. He oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease. Tom currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures, HotSpot Therapeutics, and FaunaBio.
Tom holds a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in zoology from Virginia Polytechnic Institute & State University, and a B.A. in biology from Franklin and Marshall College.
